Movement Disorders

Yi-Ting Hsu, Ya-Gin Chang, Ching-Pang Chang, Jian-Jing Siew, Hui-Mei Chen, Chon-Haw Tsai, Yijuang Chern September 10, 2017

ABSTRACT

Background: Disruptions in gamma-aminobutyric (GABA) acid signaling are believed to be involved in Huntington’s disease pathogenesis, but the regulation of GABAergic signaling remains elusive. Here we evaluated GABAergic signaling by examining the function of GABAergic drugs in Huntington’s disease and the expression of GABAergic molecules using mouse models and human brain tissues from Huntington’s disease.

Read More...
Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Claudia Trenkwalder, Reinhard Ehret, Jean Philippe Azulay, Stuart Isaacson, Larissa Felt, Mary Jean Stempien September 10, 2017

ABSTRACT

Background

The treatment of levodopa-induced dyskinesia in Parkinson’s disease (PD) is an unmet need with no approved drug therapy.

Objective

The purpose of this study was to investigate the efficacy and safety of 274 mg ADS-5102 (amantadine) extended-release capsules (equivalent to 340-mg amantadine HCl) for levodopa-induced dyskinesia in a randomized controlled trial.

Read More...
Lucilla Parnetti, Silvia Paciotti, Paolo Eusebi, Andrea Dardis, Stefania Zampieri, Davide Chiasserini, Anna Tasegian, Nicola Tambasco, Bruno Bembi, Paolo Calabresi, Tommaso Beccari September 10, 2017

Abstract

Background

Reduced β-glucocerebrosidase activity was observed in postmortem brains of both GBA1 mutation carrier and noncarrier Parkinson’s disease patients, suggesting that lower β-glucocerebrosidase activity is a key feature in the pathogenesis of PD. The objectives of this study were to confirm whether there is reduced β-glucocerebrosidase activity in the CSF of GBA1 mutation carrier and noncarrier PD patients and verify if other lysosomal enzymes show altered activity in the CSF.

Read More...
Yuan-Yang Lai, Yu-Hsuan Cheng, Kung-Chiao Hsieh, Darian Nguyen, Keng-Tee Chew, Lalini Ramanathan, Jerome M. Siegel September 10, 2017

Abstract

Background

Abnormal striatal dopamine transmission has been hypothesized to cause restless legs syndrome. Dopaminergic drugs are commonly used to treat restless legs syndrome. However, they cause adverse effects with long-term use. An animal model would allow the systematic testing of potential therapeutic drugs.

Read More...
Ambika Tewari, Rachel Fremont, Kamran Khodakhah September 10, 2017

Abstract

Dystonia is a common movement disorder that devastates the lives of many patients, but the etiology of this disorder remains poorly understood. Dystonia has traditionally been considered a disorder of the basal ganglia. However, growing evidence suggests that the cerebellum may be involved in certain types of dystonia, raising several questions.

Read More...
Pierpaolo Turcano, Michelle M. Mielke, Keith A. Josephs, James H. Bower, Joseph E. Parisi, Bradley F. Boeve, Rodolfo Savica September 10, 2017

ABSTRACT

Objective: The purpose of this study was to examine the discrepancies between the clinical diagnosis of parkinsonism and neuropathological findings in a population-based cohort with parkinsonian disorders.

Background: The specific clinical diagnosis of parkinsonism is challenging, and definite confirmation requires neuropathological evaluation.

Read More...

Andoird App
Loading...